343 related articles for article (PubMed ID: 10337430)
1. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs.
Yanni JM; Sharif NA; Gamache DA; Miller ST; Weimer LK; Spellman JM
Acta Ophthalmol Scand Suppl; 1999; (228):33-7. PubMed ID: 10337430
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs.
Yanni JM; Weimer LK; Sharif NA; Xu SX; Gamache DA; Spellman JM
Arch Ophthalmol; 1999 May; 117(5):643-7. PubMed ID: 10326962
[TBL] [Abstract][Full Text] [Related]
3. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
Galatowicz G; Ajayi Y; Stern ME; Calder VL
Clin Exp Allergy; 2007 Nov; 37(11):1648-56. PubMed ID: 17877767
[TBL] [Abstract][Full Text] [Related]
4. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
Leonardi A; Quintieri L
Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells.
Yanni JM; Miller ST; Gamache DA; Spellman JM; Xu S; Sharif NA
Ann Allergy Asthma Immunol; 1997 Dec; 79(6):541-5. PubMed ID: 9433371
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic options in ocular allergic disease.
Hingorani M; Lightman S
Drugs; 1995 Aug; 50(2):208-21. PubMed ID: 8521755
[TBL] [Abstract][Full Text] [Related]
7. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis.
Sharif NA; Xu SX; Yanni JM
J Ocul Pharmacol Ther; 1996; 12(4):401-7. PubMed ID: 8951676
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
Sharif NA; Xu SX; Miller ST; Gamache DA; Yanni JM
J Pharmacol Exp Ther; 1996 Sep; 278(3):1252-61. PubMed ID: 8819509
[TBL] [Abstract][Full Text] [Related]
9. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
Yanni JM; Stephens DJ; Miller ST; Weimer LK; Graff G; Parnell D; Lang LS; Spellman JM; Brady MT; Gamache DA
J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675
[TBL] [Abstract][Full Text] [Related]
10. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
Kida T; Fujii A; Sakai O; Iemura M; Atsumi I; Wada T; Sakaki H
Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
[TBL] [Abstract][Full Text] [Related]
11. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
Rosenwasser LJ; O'Brien T; Weyne J
Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
[TBL] [Abstract][Full Text] [Related]
12. A review of olopatadine for the treatment of ocular allergy.
Abelson MB
Expert Opin Pharmacother; 2004 Sep; 5(9):1979-94. PubMed ID: 15330735
[TBL] [Abstract][Full Text] [Related]
13. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
Abelson MB; Lanier RQ
Acta Ophthalmol Scand Suppl; 1999; (228):53-6. PubMed ID: 10337434
[TBL] [Abstract][Full Text] [Related]
14. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells.
Cook EB; Stahl JL; Barney NP; Graziano FM
Ann Allergy Asthma Immunol; 2001 Nov; 87(5):424-9. PubMed ID: 11730187
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
Fujishima H; Ohashi Y; Takamura E
Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
[TBL] [Abstract][Full Text] [Related]
16. [Allergic conjunctival disorders].
Ebihara N
Nihon Rinsho; 2005 May; 63 Suppl 5():107-13. PubMed ID: 15954334
[No Abstract] [Full Text] [Related]
17. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
Leonardi A; Abelson MB
Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
[TBL] [Abstract][Full Text] [Related]
18. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms.
Ahluwalia P; Anderson DF; Wilson SJ; McGill JI; Church MK
J Allergy Clin Immunol; 2001 Sep; 108(3):449-54. PubMed ID: 11544467
[TBL] [Abstract][Full Text] [Related]
19. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
Netland PA; Leahy C; Krenzer KL
Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
Crampton HJ
Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]